Amplify ETF Trust Amplify Natural Resources Dividend Income ETF (ARCA: NDIV)

Últimas noticias sobre Amplify ETF Trust Amplify Natural Resources Dividend Income ETF (ARCA:NDIV)

Amplify ETF Trust Amplify Natural Resources Dividend Income ETF

Energy

Basic Materials

The Fund will normally invest at least 80 Percent of its net assets (plus borrowings for investment purposes) in the securities that comprise the Index, which primarily include common stocks and/or depositary receipts. Using an indexing investment approach, the Fund attempts to replicate, before fees and expenses, the performance of the Index. The Fund generally will use a replication methodology, meaning it will invest in all of the underlying securities comprising the Index in proportion to each securitys weightings in the Index. However, the Fund may utilize a sampling methodology under various circumstances where it may not be possible or practicable to purchase all of the underlying securities in the Index. The Funds investment sub-adviser, Toroso Investments, LLC (Toroso, the Sub-Adviser) manages the investment of the Funds assets. The index provider is EQM Indexes LLC. (EQM or the Index Provider). The Index Provider is not affiliated with the Fund, the Funds investment adviser, Amplify Investments LLC (the Adviser), or the Sub-Adviser.

Petroleo Brasileiro Sa - Petrobras Adr

Western Midstream Partners Lp

Mplx Lp

Energy Transfer Lp

B2Gold Corp

Plains All American Pipeline, L.p., Series B

Enterprise Products Partners Lp

Sunoco, Lp

Dorchester Minerals L.p.

Flex Lng Ltd

Lyondellbasell Inds. Nv

Black Stone Minerals L P

Delek Logistics Partners, Lp

Alliance Resource Partners Lp

Kimbell Royalty Partners Lp

Amplify Natural Resources Dividend Income ETF

Equities

Large Cap

News

Guidance

Commodities

Movers

NDIV

OILT

Por qué las acciones de BP cayeron tras su pronóstico del 4T 2024. Cambios en producción, precios y márgenes clave para los inversores.

BP actualiza pronóstico del 4T: Impactos en producción y precios

NDIVISION INC by nDivision Inc.

NDivision Inc

Macro Economic Events

Economics

China Earlier Announced 34% Tariff On All U.S. Imports Starting April 10 In Response To U.S.Tariffs Imposed By President Trump

Telsey Advisory Group analyst Dana Telsey maintains Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) with a Market Perform and maintains $13 price target.

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Market Perform on Guess, Maintains $13 Price Target

MSSA

Metal Sky Star To Be Delisted From Nasdaq After SPAC Deadline Miss, Will Move To OTC Market

HC Wainwright &amp; Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VANI#NASDAQ">VANI</a>) with a Buy and maintains $4 price target.

Reiteration

VANI

HC Wainwright & Co. Reiterates Buy on Vivani Medical, Maintains $4 Price Target

Telsey Advisory Group analyst Joseph Feldman maintains Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Outperform and maintains $1100 price target.

COST

Telsey Advisory Group Maintains Outperform on Costco Wholesale, Maintains $1100 Price Target

UTHR

United Therapeutics Corporation Says It Will Feature Clinical Data Across Its Commercial And Development Portfolio At International Society For Heart And Lung Transplantation 45th Annual Meeting And Scientific Sessions

<ul>
<li>Late-breaking oral presentation of results from the positive pivotal ACCORD-2 Phase 3 trial of AXS-05 in Alzheimer's disease agitation&nbsp;</li>
<li>Presentation featuring network meta-analysis of SYMBRAVO versus oral CGRPs</li>
</ul>

Biotech

Health Care

General

AXSM

Axsome Therapeutics Announced Multiple Presentations At The 2025 American Academy Of Neurology Annual Meeting

NYAX

Nayax Plans To Maintain Current Hardware Pricing For US Customers, Despite New Tariffs Imposed On Imports To US

Telsey Advisory Group analyst Dana Telsey maintains G-III Apparel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) with a Market Perform and maintains $30 price target.

GIII

Telsey Advisory Group Maintains Market Perform on G-III Apparel Group, Maintains $30 Price Target

<ul>
<li>Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year.</li>
<li>Approval brings AstraZeneca and Daiichi Sankyo's Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease.</li>
</ul>

The European Commission Approves AstraZeneca And Daiichi Sankyo's Enhertu (Trastuzumab Deruxtecan) As Monotherapy For Adult Patients With Unresectable Or Metastatic Hormone Receptor-positive, HER2-low Or HER2-ultralow Breast Cancer Who Have Received At Least One Endocrine Therapy In The Metastatic Setting And Who Are Not Considered Suitable For Endocrine Therapy As The Next Line Of Treatment

ARVN

Arvinas Says It Presented First-in-Human Data For Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, And Central And Peripheral LRRK2 Degradation

In this regimen, patients are treated with Imfinzi in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery.
&nbsp;

The European Commission Approves AstraZeneca's Imfinzi (Durvalumab) In Combination With Chemotherapy For Adults With Resectable Non-small Cell Lung Cancer At High Risk Of Recurrence And No Epidermal Growth Factor Receptor Mutations Or Anaplastic Lymphoma Kinase Rearrangements

HC Wainwright &amp; Co. analyst Ed Arce reiterates Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) with a Buy and maintains $7.5 price target.

AKBA

HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $7.5 Price Target

Telsey Advisory Group analyst Cristina Fernandez maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Outperform and maintains $220 price target.

Telsey Advisory Group Maintains Outperform on Williams-Sonoma, Maintains $220 Price Target

The most oversold stocks in the consumer discretionary sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">JAKKS Pacific Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAKK#NASDAQ">JAKK</a>)</h3>
<ul>
<li>On March 18, Small Cap Consumer Research analyst Eric Beder reiterated Jakks Pacific with a Buy and maintained a $40 price target. The company's stock fell around 15% over the past five days and has a 52-week low of $17.06.</li>
<li>RSI Value: 25.2</li>
<li>JAKK Price Action: Shares of JAKKS Pacific fell 13.9% to close at $21.36 on Thursday.</li>
<li>Edge Stock Ratings: 39.60 Momentum score with Value at 94.24. </li>
</ul>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/JAKK"><img loading="lazy" decoding="async" width="437" height="177" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035725/image-40.png" alt="" class="wp-image-857015" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035725/image-40.png 437w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035725/image-40-300x122.png 300w" sizes="(max-width: 437px) 100vw, 437px" /></a></figure>
<h3 class="wp-block-heading">Haverty Furniture Companies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HVT#NYSE">HVT</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Feb. 24, Haverty Furniture reported fourth-quarter financial results and beat its EPS and revenue estimates. Steven G. Burdette, President and CEO, said, &#8220;Our team remained disciplined in managing our operations and executing our growth strategies, even amidst the housing slowdown. We achieved our goal of opening five net new stores in 2024, with a notable return to the Houston, TX market after approximately 40 years, where we now have two stores.&#8221; The company's stock fell around 17% over the past month and<a href="https://www.benzinga.com/quote/HVT"> has a 52-week low </a> of $17.78.</li>
<li>RSI Value: 27.1</li>
<li>HVT Price Action: Shares of Haverty Furniture dipped 13% to close at $17.88 on Thursday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0404">HVT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0404"><img loading="lazy" decoding="async" width="925" height="828" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035823/image-1-12.png" alt="" class="wp-image-857016" style="width:554px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035823/image-1-12.png 925w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035823/image-1-12-300x269.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035823/image-1-12-768x687.png 768w" sizes="(max-width: 925px) 100vw, 925px" /></a></figure>
<h3 class="wp-block-heading">Six Flags Entertainment Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUN#NYSE">FUN</a>)</h3>
<ul>
<li>On March 25, Truist Securities analyst Michael Swartz maintained Six Flags Entertainment with a Buy and lowered the price target from $56 to $52. The company's stock fell around 21% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/FUN">low of $31.33.</a></li>
<li>RSI Value: 27.7</li>
<li>FUN Price Action: Shares of Six Flags Entertainment fell 14.4% to close at $31.98 on Thursday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0404">FUN shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0404"><img loading="lazy" decoding="async" width="900" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035927/image-41.png" alt="" class="wp-image-857017" style="width:518px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035927/image-41.png 900w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035927/image-41-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04035927/image-41-768x711.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44626468/top-3-risk-off-stocks-that-are-ticking-portfolio-bombs">Top 3 Risk Off Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

JAKK

Top 3 Consumer Stocks That Are Set To Fly This Quarter

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates BiomX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PHGE#AMEX">PHGE</a>) with a Buy and maintains $21 price target.

PHGE

HC Wainwright & Co. Reiterates Buy on BiomX, Maintains $21 Price Target

Needham analyst Scott Berg reiterates Thryv Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRY#NASDAQ">THRY</a>) with a Buy and maintains $28 price target.

THRY

Needham Reiterates Buy on Thryv Holdings, Maintains $28 Price Target

LNZA

LanzaTech Confirms Receipt Of $0.02/Share Takeover Offer From Carbon Direct Capital, Board To Review Proposal

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) with a Buy and raises the price target from $10 to $24.

CMPX

HC Wainwright & Co. Maintains Buy on Compass Therapeutics, Raises Price Target to $24

MKTX

MarketAxess Posts Record Credit And Portfolio Trading Volumes In March And Q1 2025, Driven By 20% ADV Surge

Comments

Amplify ETF Trust Amplify Natural Resources Dividend Income ETF

Noticias

Últimas noticias sobre Amplify ETF Trust Amplify Natural Resources Dividend Income ETF (ARCA:NDIV)

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL